Publications
914
Citations
34,502
Est. group size
~18
Recurring co-author estimate
Active years
30
Publishing since 1997
Typically publishes in teams of ~11 · 3% small-team papers (≤3 authors) · across 33 venues
- Sotatercept Safety and Efficacy in Intermediate- to Low-Risk Pulmonary Arterial Hypertension
CHEST Journal · 2026
- Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death
New England Journal of Medicine · 2025
- Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis
New England Journal of Medicine · 2025
- A long-term follow-up study of sotatercept for treatment of pulmonary arterial hypertension: interim results of SOTERIA
European Respiratory Journal · 2025
- Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studies
European Respiratory Journal · 2025
- Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patients
The Lancet Respiratory Medicine · 2025
- Pericardial effusion in sotatercept phase 3 trials: insights from STELLAR and ZENITH
European Respiratory Journal · 2025
- Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in <i>BMPR2</i> Mutation Carriers and Noncarriers: A Planned Analysis of a Phase II, Double-Blind, Placebo-controlled Clinical Trial (PULSAR)
American Journal of Respiratory and Critical Care Medicine · 2025
- Characteristics of Patients with Pulmonary Arterial Hypertension Receiving Selexipag in the SPHERE Registry by Race and Ethnicity
Journal of Racial and Ethnic Health Disparities · 2025
- Evaluating oral selexipag in pulmonary arterial hypertension: Insights on survival, safety, and dosing patterns from the complete observation period of GRIPHON and its open-label extension
The Journal of Heart and Lung Transplantation · 2025
- Long-Term Safety and Exposure-Adjusted Incidence Rates of Adverse Events From Pooled Sotatercept Studies (PULSAR, SPECTRA, STELLAR, and SOTERIA)
American Journal of Respiratory and Critical Care Medicine · 2025
- Trial in Progress: PROSERA, a Phase 3 Study of the Efficacy and Safety of Seralutinib in Adults with Pulmonary Arterial Hypertension (PAH)
Pneumologie · 2025
- BURDEN OF PULMONARY ARTERIAL HYPERTENSION (PAH) ON WOMEN ACROSS REGIONS: MULTINATIONAL PATIENT QUALITATIVE STUDY
Journal of the American College of Cardiology · 2025
- Corrigendum to ‘‘Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials’’ [The Journal of Heart and Lung Transplantation, 44 (2025) 135–146]
The Journal of Heart and Lung Transplantation · 2025
- Caregiver Network and Caregiving Needs in Women With Pulmonary Arterial Hypertension (PAH)
American Journal of Respiratory and Critical Care Medicine · 2025
- The Journal of Heart and Lung Transplantation×28
- Journal of the American College of Cardiology×21
- CHEST Journal×21
- European Respiratory Journal×13
- European Heart Journal×11
- Amanda Fisher
Medicine · Indiana University
- László Farkas
Medicine · The Ohio State University
- V.V. McLaughlin
Medicine · University of Michigan
- Rachel D’Amico
Medicine · The Ohio State University
- Daniela Farkas
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile